PROTAC 工程化蛋白/DNA 纳米抗原是癌症免疫治疗中树突状细胞疫苗的有效增强剂
PROTAC-Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
优化基于树突状细胞的癌症疫苗：亚群靶向、转化障碍与新兴策略
英文原题：Refining Dendritic Cell-Based Cancer Vaccines: Subset Targeting, Translational Barriers, and Emerging Strategies.
查看英文原题
Refining Dendritic Cell-Based Cancer Vaccines: Subset Targeting, Translational Barriers, and Emerging Strategies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
树突状细胞（DC）是免疫反应的关键调节因子，能够通过抗原呈递启动强效的适应性免疫。作为最强大的抗原呈递细胞，它们已成为癌症免疫治疗的核心组成部分。在过去十年中，分子工程、生物信息学和纳米医学的进步改变了基于DC的疫苗设计。策略现在包括个性化新抗原负载、mRNA电穿孔、纳米颗粒介导的递送以及与免疫检查点抑制剂的联合方案。此外，靶向体内DC亚群的新兴方法，尤其是cDC1s，在临床前和早期临床研究中已显示出增强的疗效。本综述全面概述了DC的生物学作用，并评估了DC疫苗平台的演变，同时重点介绍了旨在抑制肿瘤诱导的免疫抑制并改善治疗结果的新技术和临床见解。
展开英文摘要原文
Dendritic cells (DCs) are pivotal regulators of immune responses, capable of initiating robust adaptive immunity through antigen presentation. As the most potent antigen-presenting cells, they have emerged as central components of cancer immunotherapy.
Over the last decade, advances in molecular engineering, bioinformatics, and nanomedicine have transformed the design of DC-based vaccines. Strategies now include personalized neoantigen loading, mRNA-electroporation, nanoparticle-mediated delivery, and combinatorial regimens with immune checkpoint inhibitors.
In addition, emerging approaches that target DC subsets in vivo , especially cDC1s, have demonstrated enhanced efficacy in preclinical and early clinical studies. This review provides a comprehensive overview of the biological roles of DCs and evaluates the evolution of DC vaccine platforms while also highlighting new technologies and clinical insights that aim to tumor-induced immunosuppression suppression and improve therapeutic outcomes.
论文信息
- 作者
- Rhee I
- 单位
- Department of Bioscience and Biotechnology, Sejong University, Seoul 05006, Republic of Korea.South Korea
- 文献类型
- 综述
- 期刊
- Journal of microbiology and biotechnology2025 Aug 12
- 原文标识
- PubMed 40825677 · DOI 10.4014/jmb.2506.06021
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →